Physician profile
Johnelle E Opel
NPI 1871234369
$7,525.39
in general payments reported to CMS, 2019-2025
21 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,040 · 2023: $1,830 · 2024: $3,036 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,441 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,440.85 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,605.94 | 2022-2025 | |
| Amgen INC. | $1,699.22 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $986.26 | 2022-2025 | |
| Janssen Biotech, INC. | $740.68 | 2022-2025 | Tremfya, Remicade, Stelara |
| Ucb, INC. | $293.86 | 2023-2025 | Cimzia, Bimzelx |
| Radius Health, INC. | $264.11 | 2022-2025 | Tymlos |
| Pfizer INC. | $193.07 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $88.13 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $86.18 | 2022-2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $68.34 | 2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $65.99 | 2024-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $64.97 | 2024-2025 | Adalimumab-Aacf |
| Genentech USA, INC. | $62.87 | 2023-2025 | Actemra |
| Vertex Pharmaceuticals Incorporated | $60.47 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $53.79 | 2025 | Strensiq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $50.61 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $46.55 | 2023 | Arcalyst |
| Organon LLC | $30.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.98 | 2024 | Purified Cortrophin Gel |
| Depuy Synthes Sales INC. | $20.90 | 2025 | Orthovisc |
| Almatica Pharma LLC | $17.47 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnelle Opel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.